Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics
JAMA Network Open · 16.01.2025 · 8 (1) · e2454938
DOI: 10.1001/jamanetworkopen.2024.54938 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 16.01.2025. Verfasst von Pedro Nascimento de Lima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Engineering and Applied Sciences Department, RAND, Arlington, Virginia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cost-Benefit Analysis, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Several noninvasive tests for colorectal cancer screening are available, but their effectiveness in settings with low adherence to screening and follow-up colonoscopy is not well documented.
Objective
To assess the cost-effectiveness of and outcomes associated with noninvasive colorectal cancer screening strategies, including new blood-based tests, in a population with low adherence to screening and ongoing surveillance colonoscopy. Design, Setting, and Participants The validated microsimulation model used for the decision analytical modeling study projected screening outcomes from 2025 to 2124 for a simulated cohort of 10 million individuals aged 50 years in 2025 and representative of a predominantly Hispanic or Latino patient population served by a Federally Qualified Health Center in Southern California. The simulated population had low adherence to first-step noninvasive testing (45%), second-step follow-up colonoscopy after an abnormal noninvasive test result (40%), and ongoing surveillance colonoscopy among patients with high-risk findings at follow-up colonoscopy (80%). Exposures Colorectal cancer screening strategies included no screening, an annual or biennial fecal immunochemical test, a triennial multitarget stool DNA test, and a triennial blood-based test. Using a blood-based test was assumed to increase first-step adherence by 17.5 percentage points. Main Outcomes and Measures Outcomes included colorectal cancer incidence and mortality, life-years gained and quality-adjusted life-years gained relative to no screening, costs, and net monetary benefit assuming a willingness to pay of $100 000 per quality-adjusted life-year gained.
Results
Under realistic adherence assumptions, a program of annual fecal immunochemical testing was the most effective and cost-effective strategy, yielding 121 life-years gained per 1000 screened individuals and a net monetary benefit of $5883 per person. Triennial blood testing was the least effective, yielding 23 life-years gained per 1000, and was not cost-effective, with a negative net monetary benefit. Annual fecal immunochemical testing with 45% first-step adherence and 80% adherence to follow-up and surveillance colonoscopy yielded greater benefit than triennial blood testing with perfect adherence (88 vs 77 life-years gained per 1000). Conclusions and Relevance This study suggests that in a federally qualified health care setting, prioritizing the convenience of blood tests over less costly and more effective existing stool-based tests could result in higher costs and worse population-level outcomes. Novel screening modalities should be carefully evaluated for performance in community settings before widespread adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Engineering and Applied Sciences Department, RAND, Arlington, Virginia.
- Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, Washington.
- Applied Mathematics Department, University of Washington, Seattle.
- University of Arizona Cancer Center, Tucson.
- Institute for Health Equity, AltaMed Health Services Corporation, Los Angeles, California.
- Fred Hutchinson Cancer Research Center, Hutchinson Institute for Cancer Outcomes Research and Biostatistics Program, Public Health Sciences Division, Seattle, Washington.
Förderung
- NCI NIH HHS
Zitieren
APA
Nascimento de Lima, P., Matrajt, L., Coronado, G., Escaron, A. L., & Rutter, C. M. (2025). Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Network Open, 8(1), e2454938. https://doi.org/10.1001/jamanetworkopen.2024.54938
Vancouver
Nascimento de Lima P, Matrajt L, Coronado G, Escaron AL, Rutter CM. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Network Open. 2025;8(1):e2454938. doi:10.1001/jamanetworkopen.2024.54938
BibTeX
@article{NascimentodeLima2025,
author = {Nascimento de Lima, Pedro and Matrajt, Laura and Coronado, Gloria and Escaron, Anne L and Rutter, Carolyn M},
title = {Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {1},
pages = {e2454938},
doi = {10.1001/jamanetworkopen.2024.54938}
}
EUVIMED